KYMRIAH (tisagenlecleucel) For Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: KYMRIAH is not indicated for the treatment of patients with primary central nervous system lymphoma. MECHANISM OF ACTION KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy that involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) to i...